Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wasserman SI | Mediators of immediate hypersensitivity. | 1983 | J. Allergy Clin. Immunol. | pmid:6193157 |
MacIntyre DE and Pollock WK | Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. | 1983 | Biochem. J. | pmid:6411067 |
Hopkins NK et al. | Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. | 1983 | Biochim. Biophys. Acta | pmid:6313071 |
Czarnetzki B | Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. | 1983 | Clin. Exp. Immunol. | pmid:6317241 |
Stimler NP and O'Flaherty JT | Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. | 1983 | Am. J. Pathol. | pmid:6624879 |
Hartung HP | Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. | 1983 | FEBS Lett. | pmid:6309563 |
Swendsen CL et al. | 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. | 1983 | Biochem. Biophys. Res. Commun. | pmid:6407484 |
Shukla SD et al. | Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. | 1983 | J. Biol. Chem. | pmid:6309795 |
Hallam TJ et al. | The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. | 1983 | FEBS Lett. | pmid:6617886 |
Roussi J et al. | [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. | 1983 | Nouv Rev Fr Hematol | pmid:6622253 |
Valone FH and Goetzl EJ | Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). | 1983 | Am. J. Pathol. | pmid:6624880 |
Barradas MA et al. | The effect of fenfluramine on collagen-induced platelet aggregation in vitro. | 1983 | Br J Clin Pharmacol | pmid:6626443 |
Korth R et al. | 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines: influence on aggregation and [3H]serotonin release of human thrombocytes. | 1983 | Chem. Phys. Lipids | pmid:6627525 |
Tence M et al. | The enantiomer and the positional isomer of platelet-activating factor. | 1983 | Biochim. Biophys. Acta | pmid:6824744 |
Camussi G et al. | Biosynthesis and release of platelet-activating factor from human monocytes. | 1983 | Int. Arch. Allergy Appl. Immunol. | pmid:6826235 |
Randolph AE et al. | Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. | 1983 | Clin Exp Hypertens A | pmid:6684006 |
Morley J et al. | Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. | 1983 | Br. J. Pharmacol. | pmid:6685552 |
Hornby EJ and Perry CR | 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. | 1983 | Thromb. Haemost. | pmid:6636035 |
Patterson R and Harris KE | The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. | 1983 | J. Lab. Clin. Med. | pmid:6644157 |
Nunn B | Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. | 1983 | Thromb. Res. | pmid:6648898 |
Myers A et al. | Glucocorticoid protection against PAF-acether toxicity in mice. | 1983 | Br. J. Pharmacol. | pmid:6652344 |
Cervoni P et al. | Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. | 1983 | Br. J. Pharmacol. | pmid:6652348 |
Ogihara T et al. | [Renomedullary hypotensive lipids and prostaglandins]. | 1983 | Horumon To Rinsho | pmid:6368051 |
Benveniste J et al. | The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. | 1983 | Br. J. Pharmacol. | pmid:6652376 |
Garcia Gil M and Sanchez Crespo M | Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. | 1983 | Immunopharmacology | pmid:6654649 |
Tokumura A et al. | Biphasic action of platelet-activating factor on isolated guinea-pig ileum. | 1983 | Lipids | pmid:6656539 |
Hamasaki Y et al. | [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. | 1983 | Kokyu To Junkan | pmid:6658209 |
Mueller HW et al. | Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils. | 1983 | J. Biol. Chem. | pmid:6406476 |
Billah MM and Johnston JM | Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. | 1983 | Biochem. Biophys. Res. Commun. | pmid:6407483 |
Valone FH and Goetzl EJ | Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. | 1983 | Immunology | pmid:6848449 |
Chilton FH et al. | Metabolic fate of platelet-activating factor in neutrophils. | 1983 | J. Biol. Chem. | pmid:6853486 |
Stormorken H et al. | A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). | 1983 | Thromb. Res. | pmid:6857589 |
Kloprogge E et al. | Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. | 1983 | Thromb. Res. | pmid:6857605 |
Chilton FH et al. | Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. | 1983 | J. Biol. Chem. | pmid:6408071 |
Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
Gonzalez-Crussi F and Hsueh W | Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. | 1983 | Am. J. Pathol. | pmid:6859226 |
Camussi G et al. | Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. | 1983 | Am. J. Pathol. | pmid:6859232 |
Sánchez-Crespo M et al. | Presence in normal human urine of a hypotensive and platelet-activating phospholipid. | 1983 | Am. J. Physiol. | pmid:6859262 |
Lumb RH et al. | Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. | 1983 | Biochim. Biophys. Acta | pmid:6860678 |
Suquet CM and Leid RW | Aggregation of equine platelets by PAF (platelet-activating factor). | 1983 | Inflammation | pmid:6862593 |
Blank ML and Snyder F | Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. | 1983 | J. Chromatogr. | pmid:6863454 |
Camussi G et al. | Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. | 1983 | Immunopharmacology | pmid:6885382 |
Hubbard JW et al. | Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. | 1983 | Life Sci. | pmid:6337313 |
Acharya SB and MacIntyre DE | Platelet products and vascular PGI2 production. | 1983 | Prostaglandins Leukot Med | pmid:6338532 |
Camussi G et al. | Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. | 1983 | Immunology | pmid:6339375 |
Billah MM and Lapetina EG | Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. | 1983 | Proc. Natl. Acad. Sci. U.S.A. | pmid:6341992 |
Lapetina EG and Siegel FL | Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. | 1983 | J. Biol. Chem. | pmid:6345519 |
Camussi G et al. | Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. | 1983 | Prostaglandins | pmid:6346397 |
Iñarrea P et al. | Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. | 1983 | Immunopharmacology | pmid:6347969 |
Satouchi K | [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. | 1983 | Seikagaku | pmid:6350499 |